Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Eli Lilly and Company recently completed a clinical study titled ‘A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.’ The study aimed to determine how much of the drug orforglipron enters the bloodstream and how long it remains when administered as capsules versus tablets. It also evaluated the safety and tolerability of these forms in overweight and obese participants.
The intervention being tested in this study is orforglipron, an orally administered drug. The study compared the bioavailability of orforglipron when given in capsule form versus tablet form, assessing how the body absorbs and processes the drug.
This Phase 1 study followed a randomized, parallel intervention model with no masking, focusing on basic science. Participants were divided into two parts, receiving different sequences of orforglipron doses as either tablets or capsules.
Key dates for this study include an actual start date of June 24, 2024, and a last update on June 23, 2025. These dates are crucial for tracking the study’s progress and ensuring timely dissemination of results.
The completion of this study could influence Eli Lilly’s stock performance by potentially enhancing investor confidence in the company’s research capabilities. As the pharmaceutical industry is highly competitive, advancements in drug delivery methods like this could offer Eli Lilly a competitive edge.
The study is now completed, with further details available on the ClinicalTrials portal.